RxDoctor Payments Data

Fuad Habash, MD

Clinical Cardiac Electrophysiology · Phoenix, AZNPI 1750764452

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (51.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 73.2% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2022 at $17,005 and has fallen 79.8% since, to $3,427 in 2025.

$42,294in general payments, 2019–2025

Across 299 payments — averaging $141.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$31K
  • Abbott$3K
  • Boston Scientific$3K
  • Biosense Webster, Inc.$3K
  • Medical Device Business Services, Inc.$817
  • Edwards Lifesciences$416
  • plus $2K from 13 others

What the payments were for

  • Grants$21,76551%
  • Travel & lodging$6,22315%
  • Food & beverage$13,68332%
  • Education$6231%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,294 in reported general payments places this provider in the 60th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

See all clinical cardiac electrophysiology providers in Arizona

Medicare billing

Part B allowed, 2024
$354,453
Medicare patients
597
Services billed
3,979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$86,599
WegovySemaglutide11$14,310
OzempicSemaglutide12$13,875
Flecainide Acetate69$4,545
Amiodarone Hcl130$3,674
Metoprolol Succinate79$1,092
Bumetanide12$785
SotalolSotalol Hcl19$478
Furosemide60$448
Tamsulosin Hcl22$228
Metoprolol Tartrate31$189
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$187
Levothyroxine Sodium26$177
Escitalopram Oxalate14$177
Potassium Chloride11$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskWegovy, Ozempic$133$28,18423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

Other clinical cardiac electrophysiology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →